Helix BioPharma Announces Collaboration with Moffitt Cancer Center

Pharmaceutical Investing

Helix BioPharma announced that it has entered into a collaboration agreement with Moffitt Cancer Center.

Helix BioPharma (TSX:HBP) announced that it has entered into a collaboration agreement with Moffitt Cancer Center.
As quoted in the press release:

Radiomic features have the potential to uncover disease characteristics that would be otherwise missed during a routine CT or PET scan analysis. These distinctive imaging features may be useful for predicting prognosis and therapeutic response for various conditions. In collaboration with Helix, the Moffitt’s Cancer Imaging and Technology Center of Excellence imaging informatics specialists will build response prediction models using delta radiomics from CT scans of patients treated with L-DOS47 in the LDOS002 Phase I monotherapy study.
Helix will be teaming up with Dr. Robert Gillies, Director of Moffitt’s Cancer Imaging and Technology Center of Excellence and the Martin Silbiger Chair of Cancer Imaging and Metabolism. Dr. Gillies has received numerous local, national and international awards for his teaching and research. His research is focused on functional and molecular imaging of cancer with an emphasis on the use of imaging to inform evolutionary models of carcinogenesis and response to therapy.
“Both Helix and the Moffitt team have a common research interest that can advance the knowledge of tumour microenvironment and how it influences carcinogenesis,” said Heman Chao, Ph.D., Chief Executive & Science Officer of Helix. “The data generated from this project may identify a prognostic phenotype which Helix can incorporate in future clinical trials with L-DOS47.”

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×